Ignite Creation Date:
2025-12-24 @ 4:21 PM
Ignite Modification Date:
2025-12-30 @ 9:11 PM
Study NCT ID:
NCT01142466
Status:
COMPLETED
Last Update Posted:
2014-02-27
First Post:
2010-06-10
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
Sponsor:
Merck KGaA, Darmstadt, Germany
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
IMP 25874
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |